Back to "Among patients with diabetes at baseline..."
Strong Support
descriptive
Analysis v3
History

In clinical studies, the rate of side effects from evolocumab was similar to that of a placebo, regardless of whether patients had diabetes or not.

73
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Blocking PCSK9 just helps the liver remove more bad cholesterol from the blood, without messing with blood sugar, immune responses, or cell health. That’s why people feel just as well on this drug as on a sugar pill, whether or not they have diabetes.

Most probable mechanism

In Simple Terms

Blocking PCSK9 lowers bad cholesterol in the blood without causing the body to react with harmful side effects, whether or not a person has diabetes, because it doesn't disrupt normal cell functions, hormone levels, or immune activity.

Causal chain
1

PCSK9 inhibition increases hepatic LDL receptor expression, enhancing clearance of low-density lipoprotein from the bloodstream

Verified by multiple studies
which leads to
2

Reduced circulating LDL cholesterol does not induce endothelial dysfunction, oxidative stress, or systemic inflammation

Verified by multiple studies
which leads to
3

No alteration in insulin sensitivity, glucose metabolism, or pancreatic beta-cell function occurs as a result of LDL reduction

Verified by multiple studies
which leads to
4

Absence of immune activation, tissue damage, or metabolic derangement prevents the initiation of adverse events unrelated to lipid lowering

Verified by multiple studies

Evidence from Studies

Supporting (1)

73

Community contributions welcome

73

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Randomized Controlled Trial
Human

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Score: 73
DOI: 10.1016/S2213-8587(17)30313-3

Similar Assertions

In people without diabetes, taking evolocumab for about two years does not raise the likelihood of developing diabetes, even in those with prediabetes. The data show no meaningful change in diabetes risk associated with this cholesterol-lowering drug.

73
0
85%

In people with prediabetes and heart disease, taking evolocumab for about two years does not increase the risk of developing diabetes, based on measurements of blood sugar levels and diabetes incidence over time.

73
0
83%

For people with heart disease who are on cholesterol-lowering drugs, adding a drug called evolocumab doesn’t raise their risk of serious side effects like diabetes or memory problems — the only real downside is a slightly higher chance of soreness at the injection site.

74
0
80%

Taking a drug called evolocumab can lower the chance of having a first major heart problem by 25% in people at high risk who’ve never had a heart attack or stroke before.

95
55
79%

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab lowers the risk of dying from any cause over five years compared to a placebo.

80
0
77%